Gilead hops straight to Phase III with once-yearly HIV PrEP shot
New Once-Yearly Lenacapavir Formulation
-
Gilead has developed two experimental once-yearly intramuscular (IM) formulations of lenacapavir for HIV pre-exposure prophylaxis (PrEP)613.
-
These formulations were tested in a Phase 1 study with 40 healthy adult participants613.
-
Both formulations (one with 5% ethanol, one with 10% ethanol) demonstrated promising pharmacokinetic profiles, maintaining lenacapavir concentrations above the efficacy threshold for over 56 weeks613.
Phase 1 Results
-
The once-yearly formulations showed sustained plasma concentrations that surpassed the twice-yearly subcutaneous formulation previously tested613.
-
No severe adverse events were reported, indicating both formulations were well-tolerated613.
-
Pre-treatment with ice helped reduce injection site pain613.
Plans for Phase 3 Trial
-
Based on the positive Phase 1 results, Gilead plans to skip Phase 2 and move directly to initiating a Phase 3 trial later in 20251613.
-
The Phase 3 trial will determine which of the two formulations to pursue for further development613.
-
This accelerated development plan aims to potentially bring a once-yearly PrEP option to market more quickly1.
Potential Impact
-
If approved, a once-yearly injectable PrEP option could improve adherence and help more people stay on PrEP consistently613.
-
It may address challenges some individuals face with daily regimens or more frequent injectable options613.
-
Gilead hopes this could ultimately help reduce new HIV infections globally613.
The rapid progression to Phase 3 reflects Gilead's confidence in lenacapavir's potential as a long-acting HIV prevention option. However, further research is still needed to confirm its safety and efficacy as a once-yearly PrEP formulation.
Sources:
1. https://www.eatg.org/hiv-news/gilead-to-test-once-a-year-hiv-prevention-shot/
6. https://www.eatg.org/hiv-news/gileads-once-yearly-lenacapavir-formulations-show-sustained-efficacy-for-hiv-prep-in-phase-1-study/
13. https://www.contagionlive.com/view/gilead-s-once-yearly-lenacapavir-formulations-show-sustained-efficacy-for-hiv-prep-in-phase-1-study